Epizyme, Inc. (NASDAQ:EPZM) Q4 2019 Earnings Conference Call - Final Transcript
Feb 24, 2020 • 08:30 am ET
Hello and welcome to Epizyme's Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. Please be advised that this call is being recorded at Epizyme's request.
I would now like to turn the call over to Alicia Davis. You may begin.
Thank you, and good morning. This morning we issued a press release outlining recent progress and our fourth quarter and year-end 2019 financial results. The press release and slides to which we'll refer can be found on our website at epizyme.com.
On the call today is Rob Bazemore, CEO; Matt Ross, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer, and Paolo Tombesi, Chief Financial Officer.
Today's discussion will include forward-looking statements related to Epizyme's current plans and expectations which are subject to certain risks and uncertainties. Actual results may differ materially due to very important factors including those described in the Risk Factors section of our most recent form 10-Q and other SEC filings. These forward-looking statements represent our views as of the call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.
Now, let me turn the call over to Rob.
Thank you all for joining us today. 2020 is already off to an incredible start. We have successfully transitioned into a fully integrated biopharmaceutical company, commercializing our first product in the U.S. and look forward to a potential second approval later this year. Our top priority is to maximize the clinical and commercial potential of TAZVERIK to further strengthen our ability to create long-term value.
TAZVERIK is now the first and only FDA approved treatment specifically indicated for epithelioid sarcoma patients and the first and only approved EZH2 inhibitor in the market. Within a week of approval, we were shipping drugs to patients. And since then we've seen verification of benefits and calls to Epizyme now not only for patients with ES, but also for patients with other INI1-negative tumors and with follicular lymphoma, or FL.
This speaks to the unmet need in these diseases, and the overall favorable profile of TAZVERIK as a new oncology treatment.
We have high expectations for the launch of TAZVERIK for ES. In evaluating our execution, we are particularly looking to see rapid adoption of TAZVERIK across all lines of ES treatment, rapid conversion of ES patients, who have been pre-identified by physicians into new prescriptions, and an increase in the number of eligible patients as a result of educational efforts, aimed at appropriate diagnosis of ES.
Our launch in ES allowed the build out of a flexible and efficiently sized commercial infrastructure. It has established our presence in the oncology field and is now being scaled up to support the potential launch in FL, given the recent acceptance of our FL NDA for filing.
As strategically intended, we were able to leverage modules from our ES NDA for our FL